In an article published in the journal mAbs Monday, executives from Adimab alleged that MIT's Ram Sasisekharan copied prior monoclonal antibody research. Visterra, a company Sasisekharan founded that had been developing one of the antibodies, was acquired by Otsuka for $430M last year.
CARB-X, the international antimicrobial consortium, has given a financial boost to 11 startups in the war against drug-resistant bacteria.
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Infectious diseases like dengue fever influenza of the seasonal and pandemic varieties are the top targets for Cambridge biotech Visterra, which has just raised a hefty Series B round – to the tune of $30 million – for its immunotherapies. The company plans to bring its influenza therapy into Phase 2 trial with the new cash […]